for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion



The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.

Official Title

A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma


Bladder Cancer Urothelial Carcinoma Metastatic Urothelial Carcinoma Renal Pelvis Carcinoma Ureter Carcinoma Urinary Bladder Carcinoma Urethra Carcinoma Muscle Invasive Bladder Cancer PARP inhibitor PARPi HRD ATLAS homologous recombination DNA repair LOH DNA defect DNA anomaly Rucaparib MIBC Carcinoma Urinary Bladder Neoplasms Carcinoma, Transitional Cell


You can join if…

Open to people ages 18 years and up

  • Have histologically or cytologically confirmed locally advanced unresectable or metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder or urethra)
  • Received 1 or 2 prior treatment regimens for advanced or metastatic disease
  • Confirmed radiologic disease progression during or following recent treatment
  • Mandatory biopsy is required during screening
  • Measurable disease per RECIST v1.1
  • Adequate organ function
  • ECOG 0 or 1

You CAN'T join if...

  • Prior treatment with a PARP inhibitor
  • Symptomatic and/or untreated CNS metastases
  • Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib


  • University of California San Diego (UCSD), Moores Cancer Center
    La Jolla California 92093 United States
  • Universityof California, Irvine
    Orange California 92868 United States


currently not accepting new patients, but might later
Start Date
Completion Date
Clovis Oncology, Inc.
Phase 2
Study Type
Last Updated